ShanXi C&Y Pharmaceutical Group Co., Ltd. (300254.SZ)
CNY 8.56
(2.27%)
CNY 8.56
(2.27%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 799.3 Million CNY | -3.58% |
| 2022 | 828.99 Million CNY | -10.9% |
| 2021 | 930.37 Million CNY | 9.7% |
| 2020 | 848.07 Million CNY | -25.07% |
| 2019 | 1.13 Billion CNY | -0.41% |
| 2018 | 1.13 Billion CNY | 21.04% |
| 2017 | 938.92 Million CNY | 25.85% |
| 2016 | 746.07 Million CNY | 9.09% |
| 2015 | 683.93 Million CNY | 4.63% |
| 2014 | 653.65 Million CNY | 27.29% |
| 2013 | 513.51 Million CNY | 42.05% |
| 2012 | 361.5 Million CNY | 16.32% |
| 2011 | 310.78 Million CNY | -2.75% |
| 2010 | 319.55 Million CNY | 31.17% |
| 2009 | 243.61 Million CNY | 19.62% |
| 2008 | 203.66 Million CNY | 0.0% |
| 2007 | 203.66 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 207.7 Million CNY | -1.85% |
| 2024 Q1 | 187.9 Million CNY | -17.35% |
| 2024 Q2 | 211.61 Million CNY | 12.62% |
| 2023 Q4 | 227.36 Million CNY | 10.18% |
| 2023 FY | 799.3 Million CNY | -3.58% |
| 2023 Q2 | 182.39 Million CNY | -0.43% |
| 2023 Q3 | 206.35 Million CNY | 13.14% |
| 2023 Q1 | 183.18 Million CNY | -6.13% |
| 2022 Q1 | 191.73 Million CNY | -9.95% |
| 2022 Q4 | 195.14 Million CNY | -14.75% |
| 2022 FY | 828.99 Million CNY | -10.9% |
| 2022 Q3 | 228.89 Million CNY | 7.35% |
| 2022 Q2 | 213.22 Million CNY | 11.21% |
| 2021 FY | 930.37 Million CNY | 9.7% |
| 2021 Q1 | 223.08 Million CNY | -10.22% |
| 2021 Q2 | 234.74 Million CNY | 5.23% |
| 2021 Q3 | 259.62 Million CNY | 10.6% |
| 2021 Q4 | 212.92 Million CNY | -17.99% |
| 2020 Q4 | 248.46 Million CNY | 21.21% |
| 2020 FY | 848.07 Million CNY | -25.07% |
| 2020 Q1 | 151.03 Million CNY | -42.27% |
| 2020 Q2 | 243.58 Million CNY | 61.28% |
| 2020 Q3 | 204.99 Million CNY | -15.84% |
| 2019 FY | 1.13 Billion CNY | -0.41% |
| 2019 Q4 | 261.6 Million CNY | -16.21% |
| 2019 Q3 | 312.2 Million CNY | 2.5% |
| 2019 Q2 | 304.58 Million CNY | 20.2% |
| 2019 Q1 | 253.39 Million CNY | -19.33% |
| 2018 Q4 | 314.11 Million CNY | 11.44% |
| 2018 Q3 | 281.87 Million CNY | 4.4% |
| 2018 FY | 1.13 Billion CNY | 21.04% |
| 2018 Q1 | 270.5 Million CNY | 0.24% |
| 2018 Q2 | 270 Million CNY | -0.18% |
| 2017 Q3 | 247.84 Million CNY | 5.05% |
| 2017 Q4 | 269.86 Million CNY | 8.88% |
| 2017 FY | 938.92 Million CNY | 25.85% |
| 2017 Q1 | 185.28 Million CNY | -16.54% |
| 2017 Q2 | 235.92 Million CNY | 27.33% |
| 2016 FY | 746.07 Million CNY | 9.09% |
| 2016 Q4 | 222.01 Million CNY | 16.26% |
| 2016 Q3 | 190.96 Million CNY | -0.92% |
| 2016 Q2 | 192.74 Million CNY | 37.33% |
| 2016 Q1 | 140.35 Million CNY | -32.55% |
| 2015 Q4 | 208.09 Million CNY | 27.5% |
| 2015 FY | 683.93 Million CNY | 4.63% |
| 2015 Q1 | 141.59 Million CNY | -26.61% |
| 2015 Q2 | 171.03 Million CNY | 20.79% |
| 2015 Q3 | 163.21 Million CNY | -4.57% |
| 2014 Q3 | 160.25 Million CNY | -2.8% |
| 2014 FY | 653.65 Million CNY | 27.29% |
| 2014 Q1 | 135.59 Million CNY | -26.93% |
| 2014 Q2 | 164.86 Million CNY | 21.59% |
| 2014 Q4 | 192.94 Million CNY | 20.4% |
| 2013 Q4 | 185.56 Million CNY | 65.2% |
| 2013 FY | 513.51 Million CNY | 42.05% |
| 2013 Q1 | 102.47 Million CNY | 1.14% |
| 2013 Q2 | 113.13 Million CNY | 10.4% |
| 2013 Q3 | 112.32 Million CNY | -0.71% |
| 2012 Q4 | 101.32 Million CNY | 2.93% |
| 2012 FY | 361.5 Million CNY | 16.32% |
| 2012 Q2 | 95.79 Million CNY | 45.3% |
| 2012 Q3 | 98.44 Million CNY | 2.76% |
| 2012 Q1 | 65.92 Million CNY | 0.76% |
| 2011 Q2 | 93.15 Million CNY | 15.34% |
| 2011 Q1 | 80.76 Million CNY | -14.03% |
| 2011 FY | 310.78 Million CNY | -2.75% |
| 2011 Q4 | 65.43 Million CNY | -8.39% |
| 2011 Q3 | 71.42 Million CNY | -23.33% |
| 2010 Q4 | 93.94 Million CNY | 37.13% |
| 2010 Q3 | 68.5 Million CNY | 0.0% |
| 2010 FY | 319.55 Million CNY | 31.17% |
| 2009 FY | 243.61 Million CNY | 19.62% |
| 2008 FY | 203.66 Million CNY | 0.0% |
| 2007 FY | 203.66 Million CNY | 0.0% |